Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMPD2 | Q01433 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.30 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51386 | 0.85 | AMPD2 (0.38) | AMPD2NCF1ALDH1A1L3MBTL1MPO | |
| Hydrochloric Acid SCHEMBL52723 | 0.84 | AMPD2 (0.37) | AMPD2NCF1ALDH1A1L3MBTL1MPO | |
| SCHEMBL12215851 | 0.78 | CRY1 (0.39) | TDP1NCF1PER2ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2528915 | 0.77 | CRY1 (0.39) | TDP1NCF1PER2ALDH1A1L3MBTL1 | |
| SCHEMBL52325 | 0.76 | FFAR4 (0.38) | AMPD2 | |
| SCHEMBL12215772 | 0.70 | CA1 (0.40) | PER2CRY1CRY2 | |
| SCHEMBL29817889 | 0.70 | ALDH1A1 (0.59) | NCF1ALDH1A1L3MBTL1MPO | |
| Hydrochloric Acid SCHEMBL2531492 | 0.69 | CA1 (0.39) | PER2ALDH1A1CRY1CRY2 | |
| SCHEMBL52688 | 0.67 | P2RX7 (0.41) | PER2ALDH1A1L3MBTL1CRY2P2RX7 | |
| Hydrochloric Acid SCHEMBL2531529 | 0.66 | P2RX7 (0.40) | PER2ALDH1A1L3MBTL1CRY2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | AMPD2 797/4885TDP1 8/4885NCF1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.